Almstead Neil Gregory, an insider at PTC Therapeutics Inc (PTCT), executed a significant sale of 108,280 shares on November 24, 2025. The shares were sold at a price of $82.61 each, bringing the total transaction value to approximately $8.95 million.
Following this sale, Gregory retains 108,280 shares of the company. Insider transactions can occur for various reasons, including diversification, tax planning, or personal financial needs. While substantial selling activity can raise questions, it does not necessarily indicate negative sentiment toward the company.
PTC Therapeutics, headquartered in Warren, New Jersey, specializes in the development of medicines for rare disorders. With a market capitalization of $6.9 billion, the company has a P/E ratio of 9.21 and an EPS of 8.53. Its therapeutic portfolio includes products like Translarna and Emflaza, which target Duchenne muscular dystrophy, as well as Upstaza, a gene therapy for AADC deficiency.
Insider transactions are reported to the SEC, providing transparency into executive actions. However, investors should consider such sales within the broader context of insider activity and company performance rather than as standalone indicators. Upcoming earnings are scheduled for May 4, 2026, with an estimated EPS of $-0.64 and revenue of $204.8 million, followed by an earnings report on August 5, 2026, with an EPS estimate of $-0.54 and revenue expectations of $222.6 million.